Ventyx Biosciences has reported encouraging top-line outcomes from its single-centre Phase IIa trial of the central nervous ...

Jefferies analysts said on Tuesday that Ventyx could leverage its mid-stage data for VTX3232 to position the oral drug ...

Ventyx Biosciences disclosed positive top-line results from its Phase 2a study of VTX3232 in patients with early-stage Parkinson's disease.

The study met its primary goal of establishing safety and tolerability of VTX3232 in patients with early-stage Parkinson’s disease CSF and plasma exposures reinforce VTX3232’s potential as a ...

VTX3232 shows safety and biomarker reduction in early Parkinson's patients; Phase 2 studies ongoing for other conditions. Quiver AI Summary. Ventyx Biosciences announced positive results from its ...

VTX3232 demonstrated an excellent pharmacokinetic profile. Steady state concentrations in CSF and plasma exceed the IC 90 for NLRP3 inhibition by ≥3-fold for a full 24-hours post-dose; ...

VTX3232 demonstrated an excellent pharmacokinetic profile. Steady state concentrations in CSF and plasma exceed the IC 90 for NLRP3 inhibition by ≥3-fold for a full 24-hours post-dose; High ...

VTX3232 is also being studied in a 12-week Phase 2 trial in participants with obesity and cardiometabolic risk factors; topline results expected in H2 2025 SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE ...

Ventyx Biosciences has shared promising top-line results from a phase 2a study of its investigational central nervous system ...

VTX3232 is a CNS-penetrant, potent and selective inhibitor of the NLRP3 inflammasome. The single-center, open-label Phase 2a study evaluated a 40mg oral daily dose of VTX3232 in ten patients with ...